Elanco, the animal health division of Eli Lilly and Company, announced January 24 that Lilly has signed an agreement to acquire ChemGen Corporation, a privately held bioscience company specializing in developing and commercializing innovative feed enzyme products that improve the efficiency of poultry, egg, and meat production. Feed enzymes are naturally occurring digestive enhancers that can help animals unlock and better use nutrients in the feed that were otherwise unavailable. Elanco is an allied leader member company of the National Chicken Council.
ChemGen will continue research and administrative operations at its current location in Gaithersburg, Maryland and manufacturing activities at its facility in Terre Haute, Indiana, as well as its present sales and field service operations. Upon closing of the transaction, ChemGen will become a wholly owned subsidiary of Lilly and an operating unit of Elanco. ChemGen currently is an allied member company of the National Chicken Council.
“Meeting the growing demand for food is one of the most critical issues of our time. The acquisition of ChemGen and its premier enzyme business further underscores Elanco’s commitment to provide our customers with leading animal productivity solutions,” said Jeff Simmons, senior vice president of Eli Lilly and Company and president of Elanco Animal Health.
